Zobrazeno 1 - 10
of 289
pro vyhledávání: '"S. Humeniuk"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
V. Vovchanska, S. Humeniuk
Publikováno v:
Pedagogy of the formation of a creative person in higher and secondary schools. 1:60-63
Autor:
S. Humeniuk
Publikováno v:
Епістемологічні дослідження у філософії, соціальних і політичних науках, Vol 2, Iss 23 (2013)
У статті здійснено аналіз історико-філософського періоду кінця ХVI-го початку – ХVII ст. та перших тенденційних спроб римокатоликів, сере
Externí odkaz:
https://doaj.org/article/81a93e9d0da94db0aff1fa1d72dcb3cc
Autor:
Yuan Wu, Rajan T. Gupta, Michael R. Harrison, Daniel J. George, Andrew J. Armstrong, Michael S. Humeniuk, Tian Zhang, Patrick Healy, Sundhar Ramalingam, Megan Ann McNamara
Publikováno v:
Prostate Cancer and Prostatic Diseases. 21:92-99
Platinum-based chemotherapy is effective in men with neuroendocrine prostate cancer (NEPC), but it is unclear whether histology (adenocarcinoma vs. non-adenocarcinoma NEPC variants) is predictive of platinum sensitivity. Given that NEPC exists as a s
Publikováno v:
Cancer. 123:3441-3444
Autor:
Michael S, Humeniuk
Publikováno v:
Clinical advances in hematologyoncology : HO. 17(3)
Autor:
Michael S. Humeniuk, Catrin Davies, Monika Anand, Susan Halabi, Andrew J. Armstrong, Michael R. Harrison, Tian Zhang, Jiaoti Huang, Daniel J. George, Landon Carter Brown, Yuan Wu, Taofik Oyekunle
Publikováno v:
Journal of Clinical Oncology. 39:89-89
89 Background: Men with metastatic neuroendocrine/small cell and aggressive variant prostate cancer (NEPC/AVPC) have poor outcomes despite platinum and taxane chemotherapy. These tumors share common features with small cell lung cancer, including hig
Autor:
Carolyn Winters, Michael S. Humeniuk, Michael R. Harrison, Russell Z. Szmulewitz, Daniel J. George, Elia Martinez, Susan Halabi, Patrick Healy, Andrew J. Armstrong, Julie Kephart, Kelly Mundy
Publikováno v:
The Prostate. 77:385-395
BACKGROUND Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single ag
Autor:
Michael S. Humeniuk, Darrell R. Schroeder, Joshua S. Shapiro, Neelima Bonthu, Mustaqeem A. Siddiqui, Deanne T. Kashiwagi
Publikováno v:
American Journal of Medical Quality. 32:526-531
Little is known about which variables put patients with cancer at risk for 30-day hospital readmission. Comanagement of this often complex patient population by specialists and hospitalists has become increasingly common. This retrospective study exa
Publikováno v:
Evidence-Based Urology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13f39364c4eef273e8b8986f962fd668
https://doi.org/10.1002/9781119129875.ch28
https://doi.org/10.1002/9781119129875.ch28